会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
    • N-乙内酰胺的结晶形式,其制备方法和包含其的药物组合物
    • KR100837843B1
    • 2008-06-13
    • KR1020060134115
    • 2006-12-26
    • 씨제이제일제당 (주)
    • 송석범조일환고동현임동권김영주
    • C07C233/63C07C231/24A61K31/192
    • A crystal form I of nateglinide, a method for preparing the crystal form I, and a composition for treating diabetes containing the crystal form I are provided to improve fluidity and stability and to reduce volume density. A crystal form I of nateglinide is such that it has a peak at a 2theta diffraction angle of at least 7.54, 10.5, 13.5, 15.1, 15.7, 16.1, 18.6, 19.2, 19.8, 20.9 and 22.4±0.2 in X-ray powder diffraction pattern. Preferably the crystal form I of nateglinide has a melting point of 130-132 deg.C. The crystal form I of nateglinide is prepared by adding a nateglinide solution in isopropanol to water drop by drop at 10-25 deg.C to form crystal, wherein the amount of isopropanol is 15-20 vol% to the total amount of isopropanol and water.
    • 那格列奈的晶型I,晶型I的制备方法和用于治疗含有晶型I的糖尿病的组合物被提供以提高流动性和稳定性并降低体积密度。 那格列奈的晶型I使得其在X射线粉末衍射中的2θ衍射角具有至少7.54,10.5,13.5,15.1,15.7,16.1,18.6,19.2,19.8,20.9和22.4±0.2的峰值 模式。 那格列奈的晶型I优选的熔点为130-132℃。 那格列奈的晶型I通过在10-25℃下逐滴加入异丙醇中的那格列奈溶液来形成晶体,其中异丙醇的量相对于异丙醇和水的总量为15-20体积% 。